Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGSQ Argos Therapeutics	$0.05	$0.05	$0.02 ▼ $0.25	$572K	2.47	13,394 shs	N/A
BSPM Biostar Pharmaceuticals		$0.00	$0.00 ▼ $0.00	N/A	-2.3	N/A	N/A
HSTC HST Global	$0.28	$0.61	$0.23 ▼ $1.10	$15.89M	-1.24	213 shs	N/A
SKVI Skinvisible	$0.20	$0.21	$0.16 ▼ $0.85	$1.08M	1.76	92 shs	70 shs
TRPXD Therapix Biosciences		$0.00	$2.75 ▼ $22.40	$299K	N/A	1,852 shs	900 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGSQ Argos Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
BSPM Biostar Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+∞
HSTC HST Global	0.00%	-8.64%	-46.29%	-66.87%	-73.81%
SKVI Skinvisible	0.00%	-25.09%	+13.44%	-33.33%	-71.01%
TRPXD Therapix Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGSQ Argos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BSPM Biostar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HSTC HST Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SKVI Skinvisible	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRPXD Therapix Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGSQ Argos Therapeutics	N/A	N/A	N/A
BSPM Biostar Pharmaceuticals	N/A	N/A	N/A
HSTC HST Global	N/A	N/A	N/A
SKVI Skinvisible	N/A	N/A	N/A
TRPXD Therapix Biosciences	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGSQ Argos Therapeutics	$1.90M	0.30	N/A	N/A	($1.63) per share	-0.03
BSPM Biostar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
HSTC HST Global	N/A	N/A	N/A	N/A	N/A	N/A
SKVI Skinvisible	$20K	54.00	N/A	N/A	($1.86) per share	-0.11
TRPXD Therapix Biosciences	N/A	N/A	N/A	N/A	$0.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGSQ Argos Therapeutics	-$40.57M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
BSPM Biostar Pharmaceuticals	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
HSTC HST Global	-$150K	-$0.02	N/A	∞	N/A	N/A	N/A	N/A	N/A
SKVI Skinvisible	-$570K	-$0.10	N/A	∞	N/A	-2,780.00%	N/A	-359.02%	N/A
TRPXD Therapix Biosciences	-$4.79M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest ARGSQ, SKVI, TRPXD, BSPM, and HSTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	SKVI Skinvisible	N/A	-$0.05	N/A	-$0.05	N/A	$0.01 million
4/14/2025	Q4 2024	SKVI Skinvisible	N/A	$0.08	N/A	$0.08	N/A	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGSQ Argos Therapeutics	N/A	N/A	N/A	N/A	N/A
BSPM Biostar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HSTC HST Global	N/A	N/A	N/A	N/A	N/A
SKVI Skinvisible	N/A	N/A	N/A	N/A	N/A
TRPXD Therapix Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGSQ Argos Therapeutics	N/A	N/A	N/A
BSPM Biostar Pharmaceuticals	N/A	N/A	N/A
HSTC HST Global	N/A	N/A	N/A
SKVI Skinvisible	N/A	0.01	0.01
TRPXD Therapix Biosciences	N/A	0.49	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGSQ Argos Therapeutics	N/A
BSPM Biostar Pharmaceuticals	N/A
HSTC HST Global	N/A
SKVI Skinvisible	N/A
TRPXD Therapix Biosciences	14.32%

Insider Ownership

Company	Insider Ownership
ARGSQ Argos Therapeutics	28.21%
BSPM Biostar Pharmaceuticals	17.20%
HSTC HST Global	65.82%
SKVI Skinvisible	53.00%
TRPXD Therapix Biosciences	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGSQ Argos Therapeutics	122	10.59 million	N/A	Not Optionable
BSPM Biostar Pharmaceuticals	200	N/A	N/A	Not Optionable
HSTC HST Global	1	57.77 million	19.75 million	Not Optionable
SKVI Skinvisible	2	5.40 million	2.54 million	Not Optionable
TRPXD Therapix Biosciences	8	50,000	N/A	Not Optionable

ARGSQ, SKVI, TRPXD, BSPM, and HSTC Headlines

Recent News About These Companies

TRON (CRYPTO: TRX)

February 13, 2024 | fool.com

Paddle Healthy: TRX Workout

September 28, 2023 | mensjournal.comM

Dead: RAM 1500 TRX

September 24, 2023 | jalopnik.comJ

2024 Ram 1500 TRX Final Edition Brings the End

September 19, 2023 | autoweek.comA

Used 2010 Dodge Ram 1500 TRX trucks for sale near me

August 12, 2023 | cars.comC

T. Rowe Price Retirement I 2040 I

February 23, 2023 | morningstar.comM

Used 2022 RAM 1500 TRX trucks for sale in Dallas, TX

February 18, 2023 | cars.comC

The 2023 Chevy Silverado ZR2 Is More Well-Rounded Than the Raptor or TRX

January 1, 2023 | jalopnik.comJ

2022 Ram 1500 TRX

October 25, 2022 | caranddriver.comC

TRX-Duo Is A Red Pitaya Clone For Software Defined Radio

October 13, 2022 | hackaday.comH

Media Sentiment Over Time

ARGSQ, SKVI, TRPXD, BSPM, and HSTC Company Descriptions

Argos Therapeutics OTCMKTS:ARGSQ

$0.05 0.00 (0.00%)

As of 10/10/2019

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

Biostar Pharmaceuticals OTCMKTS:BSPM

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.

HST Global OTCMKTS:HSTC

$0.28 0.00 (0.00%)

As of 07/11/2025

HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.

Skinvisible OTCMKTS:SKVI

$0.20 0.00 (0.00%)

As of 07/11/2025

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

Therapix Biosciences OTCMKTS:TRPXD

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time